Biodegradable Polymer DES (Ultimaster) vs. Magnesium Bioresorbable Scaffold (BRS Magmaris) in Diabetic Population with NSTE-ACS: A One-Year Clinical Outcome of Two Sirolimus-Eluting Stents

Table 2

Procedural characteristics of both study arms.

	Magmaris group			Ultimaster group
Procedural characteristic	DM; ()	Non-DM; ()	value	DM; ()	Non-DM; ()	value
Treated vessel: LAD	31 (43%)	49 (40.5%)		21 (35.5%)	44 (40%)
LCX	18 (25%)	31 (25.6%)		19 (32.2%)	28 (25.4%)
RCA	22 (30.6%)	39 (32.2%)		18 (30.5%)	38 (34.5%)
IM	1 (1.4%)	2 (1.7%)		1 (1.6%)	0
Predilatation balloon:
(i) Mean diameter (mm)
(ii) Mean pressure (atm)
Average scaffold number
Average scaffold diameter:
Average scaffold length (mm)
Postdilatation balloon:
(i) Mean diameter (mm)
Mean pressure (atm)
(i) 0.0 mm greater than scaffold	12 (16.6%)	19 (15.7%)		42 (71.1%)	78 (70.9%)
(ii) 0.25 mm greater than scaffold	47 (65.2%)	83 (68.6%)		11 (18.6%)	24 (21.8%)
(iii) 0.5 mm greater than scaffold	13 (18.2%)	19(15.7%)		6 (10.1%)	8 (7.2%)
Contrast volume (mL)
Radiation dose (mGy)
OCT-guided PCI	13 (18%)	28 (23.1%)		9 (15.2%)	19 (17.2%)
Perforation of vessel	0 (0%)	0	—	0	0	—
Side branch occlusion	0 (0%)	2 (1.6%)		1 (1.6%)	0
Drugs: ASA	72 (100%)	121 (100%)	—	59 (100%)	109 (99.1%)
Clopidogrel	26 (36.1%)	50 (41.3%)		52 (88.1%)	97 (88.1%)
Ticagrelor	46 (63.9%)	71 (58.7%)		7 (11.8%)	13 (11.8%)
Statin	71 (98.6%)	119 (98.3%)		58 (98.3%)	110 (100%)
ACEI/ARB	61 (84.7%)	100 (82.6%)		55 (93.2%)	99 (90%)
B-blocker	64 (88.8%)	106 (87.6%)		55 (93.2%)	97 (88.1%)

Abbreviations: OCT: optical coherence tomography; PCI: percutaneous coronary intervention; ASA: acetylsalicylic acid; ACEI: angiotensin-converting enzyme inhibitors; ARB: angiotensin receptor blockers.